Massey, Paul R.
Gupta, Sameer
Rothstein, Brooke E.
Konnikov, Nellie
Mahalingam, Meera
Ruiz, Emily S.
Schmults, Chrysalyne D.
Waldman, Abigail
Article History
Received: 2 August 2020
Accepted: 4 December 2020
First Online: 19 March 2021
Disclousure
: Chrysalyne Schmults has been a steering committee member for Castle Biosciences; a steering committee member and consultant for Regeneron Pharmaceuticals; and a consultant for Sanofi. She has also received research funding from Castle Biosciences, Regeneron Pharmaceuticals, Novartis, Genentech, and Merck, and is a chair for the NCCN. Emily S. Ruiz has been a consultant for Sanofi, Pellepharm Inc, and Jounce and is also on the advisory board for Leo Pharma and Checkpoint Therapeutics. Paul R. Massey, Sameer Gupta, Brooke E. Rothstein, Nellie Konnikov, Meera Mahalingam, and Abigail Waldman have no conflicts of interest to declare.